Clinical Trials Browser

Phase 2 × Urinary Bladder Neoplasms × Cisplatin × Clear all

NCT06770582 2026-04-15

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT02690558 2026-03-20

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Phase 2 Completed

39 enrolled 16 charts

Urinary Bladder Neoplasms

NCT07332351 2026-03-13

TRIFECTA

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04630730 2026-01-21

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT06091124 2025-12-08

NEOBLAST

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT05975307 2025-12-01

BCIRT-01

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT04216290 2025-11-12

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT07184021 2025-09-19

No Acronym

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT04383743 2025-09-18

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

Phase 2 Completed

17 enrolled 12 charts

Urinary Bladder Neoplasms

NCT00082706 2025-09-09

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Phase 2 Active not recruiting

Urachal cancer, Urinary Bladder Neoplasms, Urethral Neoplasms

NCT04887831 2025-09-08

PRESERVE3

Phase 2 Terminated

92 enrolled 24 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06571708 2025-09-02

NeoSTOP-IT

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06983210 2025-08-14

GRAPE

Phase 2 Recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT05312671 2025-06-29

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT02662062 2025-01-27

PCR-MIB

Phase 2 Completed

28 enrolled 15 charts

Urinary Bladder Neoplasms

NCT04861584 2024-12-04

Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT00981656 2024-09-19

Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer

Phase 2 Completed

37 enrolled 19 charts

Urinary Bladder Neoplasms

NCT02177695 2024-09-19

COXEN

Phase 2 Completed

237 enrolled 20 charts

Urinary Bladder Neoplasms

NCT05531123 2024-07-12

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03558087 2024-06-27

Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

Phase 2 Completed

76 enrolled 14 charts

Urinary Bladder Neoplasms

NCT04430036 2024-04-04

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

Phase 2 Terminated

4 enrolled 9 charts

Urinary Bladder Neoplasms

NCT03617913 2023-01-06

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Phase 2 Completed

2 enrolled 8 charts

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT00777491 2022-06-15

Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

Phase 2 Completed

70 enrolled 18 charts

Urinary Bladder Neoplasms

NCT03294304 2021-12-16

BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

Phase 2 Completed

43 enrolled 20 charts

Urinary Bladder Neoplasms

NCT03520231 2021-11-23

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

NCT00006111 2021-02-21

Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract

Phase 2 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT01589094 2019-10-02

Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

Phase 2 Completed

51 enrolled 11 charts

Urinary Bladder Neoplasms

NCT01611662 2019-07-29

Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer

Phase 2 Terminated

32 enrolled 6 charts

Urinary Bladder Neoplasms

NCT02560038 2018-11-28

Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer

Phase 2 Terminated

3 enrolled 9 charts

Urinary Bladder Neoplasms, Neoplasm Metastasis

NCT01089088 2018-10-26

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Phase 2 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00310011 2018-08-10

Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium

Phase 2 Completed

Urinary Bladder Neoplasms

NCT00268450 2018-07-12

Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery

Phase 2 Terminated

21 enrolled 4 charts

Urinary Bladder Neoplasms

NCT00055601 2018-06-15

Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer

Phase 2 Completed

97 enrolled 8 charts

Urinary Bladder Neoplasms

NCT01828736 2017-02-06

CVH-CT02

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00808639 2016-10-24

Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

Phase 2 Completed

39 enrolled 7 charts

Urinary Bladder Neoplasms

NCT01454089 2016-10-07

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT00645593 2016-05-23

Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer

Phase 2 Completed

89 enrolled 10 charts

Urinary Bladder Neoplasms

NCT00506155 2016-03-31

Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer

Phase 2 Completed

60 enrolled 10 charts

Urinary Bladder Neoplasms

NCT00234494 2016-03-14

Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer

Phase 2 Completed

45 enrolled 11 charts

Urinary Bladder Neoplasms

NCT00847015 2016-02-29

Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Phase 2 Completed

18 enrolled 8 charts

Urinary Bladder Neoplasms

NCT00714948 2015-11-16

Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2 Terminated

2 enrolled 5 charts

Urinary Bladder Neoplasms

NCT00635726 2015-10-08

Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer

Phase 2 Terminated

Urinary Bladder Neoplasms

NCT01639521 2014-01-29

Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

Phase 2 Withdrawn

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT00005086 2013-09-05

Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer

Phase 2 Completed

Urinary Bladder Neoplasms

NCT00006105 2013-09-05

Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer

Phase 2 Completed

Urinary Bladder Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT01222676 2013-08-12

Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder

Phase 2 Unknown

Urinary Bladder Neoplasms

NCT00516750 2013-07-10

Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin

Phase 2 Terminated

Urinary Bladder Neoplasms

NCT00002684 2013-07-03

Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer

Phase 2 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms